Leerink Partnrs Decreases Earnings Estimates for Climb Bio

Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 EPS estimates for Climb Bio in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($0.66) for the year, down from their prior estimate of ($0.65). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio's FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.14) EPS and FY2028 earnings at ($1.77) EPS.

Separately, Leerink Partners began coverage on Climb Bio in a report on Monday, December 2nd. They issued an "outperform" rating and a $10.00 price objective on the stock.

Climb Bio Stock Performance

Shares of CLYM traded up $0.08 during trading hours on Monday, hitting $1.59. The stock had a trading volume of 748,820 shares, compared to its average volume of 464,842. Climb Bio has a 12-month low of $1.50 and a 12-month high of $11.55. The company has a market capitalization of $106.88 million, a price-to-earnings ratio of -0.75 and a beta of -0.24. The stock has a fifty day simple moving average of $2.05.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.